VYNE Therapeutics
$0.6485
53
-$0.02-2.47% Friday 20:00
Statistics
Day High
0.665
Day Low
0.645
52W High
1.77
52W Low
0.287
Volume
82,600
Avg. Volume
-
Mkt Cap
21.61M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
19AugExpected
Expected EPS
-0.18
Actual EPS
N/A
Financials
-4,646.14%Profit Margin
Unprofitable1.14MRevenue
-52.97MNet Income
People Also Follow
This list is based on the watchlists of people on Stock Events who follow VYNE. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap191.7B
Abbvie
ABBV
Mkt Cap402.35B
Johnson & Johnson
JNJ
Mkt Cap579.83B
Pfizer
PFE
Mkt Cap149.38B
Merck
MRK
Mkt Cap294.03B
Gilead Sciences
GILD
Mkt Cap155.93B
Regeneron Pharmaceuticals
REGN
Mkt Cap64.18B
Novartis
NVS
Mkt Cap292.07B
Bristol-Myers Squibb
BMY
Mkt Cap116.66B
Astrazeneca
AZN
Mkt Cap277.22B
About
VYNE Therapeutics Inc. is a pharmaceutical enterprise dedicated to discovering and advancing therapies for immune-mediated inflammatory conditions. Its development portfolio features FCD105, a topical foam formulation that has successfully finished Phase III clinical studies for the management of moderate-to-severe acne vulgaris. Another candidate in its pipeline is FMX114, a combination treatment incorporating tofacitinib, which is currently in early-stage clinical assessment, referred to as a Phase IIa preclinical trial, for addressing mild-to-moderate atopic dermatitis. Additionally, the company is progressing VYN201, a bromodomain and extra-terminal (BET) inhibitor designed to target a range of immuno-inflammatory disorders, notably those affecting the skin. A further asset is VYN202, which comprises BET inhibitor compounds engineered for selective action on bromodomain 2. Established in 2003, the firm was formerly recognized as Menlo Therapeutics Inc. before officially changing its corporate identity to VYNE Therapeutics Inc. in September 2020. The company's principal operations are based in Bridgewater, New Jersey.
Show more...
CEO
Mr. David T. Domzalski
Employees
13
Country
United States
ISIN
US92941V3087
Listings
0 Comments
Share your thoughts
FAQ
What is VYNE Therapeutics stock price today?▼
The current price of VYNE is $0.65 USD — it has decreased by -2.47% in the past 24 hours. Watch VYNE Therapeutics stock price performance more closely on the chart.
What is VYNE Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange VYNE Therapeutics stocks are traded under the ticker VYNE.
Is VYNE Therapeutics stock price growing?▼
VYNE stock has fallen by -1.53% compared to the previous week, the month change is a -3.21% fall, over the last year VYNE Therapeutics has showed a -27.9% decrease.
What is VYNE Therapeutics market cap?▼
Today VYNE Therapeutics has the market capitalization of 21.61M
When is the next VYNE Therapeutics earnings date?▼
VYNE Therapeutics is going to release the next earnings report on August 19, 2026.
What is VYNE Therapeutics revenue for the last year?▼
VYNE Therapeutics revenue for the last year amounts to 1.14M USD.
What is VYNE Therapeutics net income for the last year?▼
VYNE net income for the last year is -52.97M USD.
How many employees does VYNE Therapeutics have?▼
As of June 15, 2026, the company has 13 employees.
In which sector is VYNE Therapeutics located?▼
VYNE Therapeutics operates in the Health & Wellness sector.
When did VYNE Therapeutics complete a stock split?▼
The last stock split for VYNE Therapeutics was on February 13, 2023 with a ratio of 1:18.
Where is VYNE Therapeutics headquartered?▼
VYNE Therapeutics is headquartered in Stewartsville, United States.